Methazolamide structure
|
Common Name | Methazolamide | ||
---|---|---|---|---|
CAS Number | 554-57-4 | Molecular Weight | 236.272 | |
Density | 1.8±0.1 g/cm3 | Boiling Point | 402.0±28.0 °C at 760 mmHg | |
Molecular Formula | C5H8N4O3S2 | Melting Point | 208ºC (dec.) | |
MSDS | Chinese USA | Flash Point | 196.9±24.0 °C | |
Symbol |
GHS07, GHS08 |
Signal Word | Warning |
Use of MethazolamideMethazolamide is a carbonic anhydrase inhibitor used to treat glaucoma.Target: Carbonic AnhydraseMethazolamide is a carbonic anhydrase inhibitor with Ki of 50 nM, 14 nM and 36 nM for hCA I, hCA II and bCA IV isoforms, respectively [1]. Methazolamide is of strength equal to acetazolamide, another carbonic anhydrase inhibitor used to treat irregular breathing disorders. However, methazolamide differs from acetazolamide in that it fails to activate Ca2+-dependent potassium channels in skeletal muscles. Methazolamide does not impair respiratory work performance in anesthetized rabbits [2]. Oral administration of methazolamide decreases IOPs and AHFRs in clinically normal dogs, with effectiveness diminishing in the evening [3]. |
Name | Methazolamide |
---|---|
Synonym | More Synonyms |
Description | Methazolamide is a carbonic anhydrase inhibitor used to treat glaucoma.Target: Carbonic AnhydraseMethazolamide is a carbonic anhydrase inhibitor with Ki of 50 nM, 14 nM and 36 nM for hCA I, hCA II and bCA IV isoforms, respectively [1]. Methazolamide is of strength equal to acetazolamide, another carbonic anhydrase inhibitor used to treat irregular breathing disorders. However, methazolamide differs from acetazolamide in that it fails to activate Ca2+-dependent potassium channels in skeletal muscles. Methazolamide does not impair respiratory work performance in anesthetized rabbits [2]. Oral administration of methazolamide decreases IOPs and AHFRs in clinically normal dogs, with effectiveness diminishing in the evening [3]. |
---|---|
Related Catalog | |
References |
Density | 1.8±0.1 g/cm3 |
---|---|
Boiling Point | 402.0±28.0 °C at 760 mmHg |
Melting Point | 208ºC (dec.) |
Molecular Formula | C5H8N4O3S2 |
Molecular Weight | 236.272 |
Flash Point | 196.9±24.0 °C |
Exact Mass | 236.003784 |
PSA | 144.03000 |
LogP | 0.13 |
Vapour Pressure | 0.0±0.9 mmHg at 25°C |
Index of Refraction | 1.737 |
Storage condition | 2-8°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Symbol |
GHS07, GHS08 |
---|---|
Signal Word | Warning |
Hazard Statements | H302 + H312 + H332-H351 |
Precautionary Statements | P261-P280-P301 + P312 + P330 |
Hazard Codes | Xn:Harmful |
Risk Phrases | R20/21/22;R40 |
Safety Phrases | S22-S36 |
RIDADR | NONH for all modes of transport |
WGK Germany | 3 |
RTECS | AC6350000 |
HS Code | 2935009090 |
Precursor 1 | |
---|---|
DownStream 0 |
HS Code | 2935009090 |
---|---|
Summary | 2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0% |
Inhibition of hyperactivity and impulsivity by carbonic anhydrase inhibitors in spontaneously hypertensive rats, an animal model of ADHD.
Psychopharmacology 232 , 3763-72, (2015) Dysregulation of noradrenergic and dopaminergic systems is involved in the pathology of attention deficit hyperactivity disorder (ADHD). Carbonic anhydrase (CA) has been reported to affect monoamine t... |
N-[(2E)-5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide |
methazolamide |
Methazolamide [BAN:INN:JAN] |
Acetamide, N-[(2E)-5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]- |
Methazolamide (JAN/USP) |
EINECS 209-066-7 |
N-(4-Methyl-2-sulfamoyl-D2-1,3,4-thiadiazolin-5-ylidene)acetamide |
Metazolamide [DCIT] |
Acetamide, N-[(2Z)-5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]- |
5-Acetylamino-4-methyl-D2-1,3,4-thiadiazoline-2-sulfonamide |
NEPTAZANE |
N1-[5-(aminosulfonyl)-3-methyl-2,3-dihydro-1,3,4-thiadiazol-2-yliden]acetamide |
4-27-00-08221 (Beilstein Handbook Reference) |
N-[(2Z)-3-Methyl-5-sulfamoyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide |
N-[5-(Aminosulfonyl)-3-methyl-1,3,4-triadiazol-2(3H)-ylidene]acetamide |
N-[(2E)-3-Methyl-5-sulfamoyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide |
MFCD00083416 |
N-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2-ylidene)acetamide |